Orient Europharma Co Ltd (4120) — Cash Flow Reinvestment Rate

Latest as of June 2025: 44.08x

Orient Europharma Co Ltd (4120) has a Cash Flow Reinvestment Rate of 44.08x as of June 2025, reinvesting NT$1.47 Billion (capex NT$89.03 Million plus investments NT$1.38 Billion) from operating cash flow of NT$33.25 Million. See Orient Europharma Co Ltd free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

44.08x
(Capex + Investments) / Operating CF

Total Reinvested

NT$1.47 Billion
Capex + Investments

Operating Cash Flow

NT$33.25 Million
TWD

Capital Expenditures

NT$89.03 Million
TWD

Orient Europharma Co Ltd Cash Flow Reinvestment Rate (2015–2023)

Historical reinvestment intensity for Orient Europharma Co Ltd across 8 annual periods. For the full cash flow conversion analysis, see Orient Europharma Co Ltd (4120) cash conversion ratio.

Annual Cash Flow Reinvestment Rate for Orient Europharma Co Ltd (2015–2023)

Year-by-year capital reinvestment analysis for Orient Europharma Co Ltd. See Orient Europharma Co Ltd (4120) flexibility index to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (TWD) Operating CF Capex YoY Change
2023 5.44x NT$351.83 Million NT$64.67 Million NT$100.70 Million ▼ -75.1%
2021 21.89x NT$1.70 Billion NT$77.65 Million NT$1.56 Billion ▲ +3647.9%
2020 0.58x NT$355.35 Million NT$608.55 Million NT$232.78 Million ▲ +4.4%
2019 0.56x NT$127.14 Million NT$227.37 Million NT$124.98 Million ▼ -36.0%
2018 0.87x NT$202.21 Million NT$231.31 Million NT$201.61 Million ▲ +9.7%
2017 0.80x NT$478.86 Million NT$601.08 Million NT$367.66 Million ▼ -85.4%
2016 5.47x NT$608.30 Million NT$111.24 Million NT$224.81 Million ▲ +912.9%
2015 0.54x NT$347.66 Million NT$643.97 Million NT$229.54 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow